CTRI/2021/10/037406进行中（未招募）4 期
Phase 4, Multicenter, Prospective, Interventional, Post-Marketing Study in Hemophilia A Patients in India Receiving ADVATE as On-Demand or Prophylaxis Under Standard Clinical Practice - Nil
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. The subject or legally authorized representative (in case of study participants <18 years of age) gave written informed consent to participate in the study.
- •2. Subject of any age with hemophilia A.
- •3. Subject is defined as previously treated patient (PTP):
- •Subject aged >= 6 years that has been previously treated with plasma-derived and/or recombinant FVIII concentrate(s) for a minimum of 150 exposure days (EDs).
- •Subject aged < 6 years that has been previously treated with plasma-derived and/or recombinant FVIII concentrate(s) for a minimum of 50 EDs.
- •4. Subject has negative history of FVIII inhibitors and negative inhibitor at screening defined as less than 0.6 Bethesda units (BU)/mL (Nijmegen-modified Bethesda assay).
- •5. Subject is human immunodeficiency virus negative (HIV-); or HIV+ with stable disease and CD4+ count >= 200 cells/mm3, as confirmed by central laboratory at screening.
- •6. Subject is hepatitis C virus negative (HCV-) by antibody or polymerase chain reaction (PCR) testing (if positive, antibody titer will be confirmed by PCR), as confirmed by central laboratory at screening; or HCV+ with chronic stable hepatitis.
- •7. The subject is willing and able to comply with the requirements of the protocol
排除标准
- •1. Subject has known hypersensitivity to mouse or hamster proteins or to any of the excipients of FVIII concentrates.
- •2. Subject has been diagnosed with bleeding disorder(s) other than congenital hemophilia A, such as acquired hemophilia A, von Willebrand´s disease or thrombocytopenia (platelet count <100,000/mL).
- •3. Subject has received treatment for hemophilia A with non-FVIII products/concentrates (eg, emicizumab [Hemlibra®]) in the 6 months prior to screening.
- •4. Subject has severe chronic hepatic dysfunction [eg, >= 5 times upper limit of normal alanine aminotransferase (ALT), aspartate aminotransferase (AST) or INR > 1.5 as confirmed by central laboratory at screening].
- •5. Subject has planned, or is likely to have, surgery during the study period.
- •6. Subject has a clinically significant medical, psychiatric, or cognitive illness, or recreational drug/alcohol use that, in the opinion of the investigator, would affect subjectâ??s safety or compliance.
- •7. Subject is currently receiving or is scheduled to receive during the course of the study, an immunomodulating drug (eg, corticosteroid agents at a dose equivalent to hydrocortisone greater than mg/day, or α-interferon) other than antiretroviral chemotherapy.
- •8. Subject has participated in another clinical study involving an investigational product (IP) or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.
- •9. Subject is a family member or employee of the investigator.
研究者
相似试验
进行中（未招募）
1 期
A Study of ADVATE in People With Hemophilia A in IndiaHemophilia AEUCTR2022-004149-11-Outside-EU/EEATakeda Biopharmaceuticals India Pvt. Ltd.50
进行中（未招募）
1 期
A Post Marketing Surveillance (PMS) Study of RIXUBIS in IndiaHemophilia BEUCTR2022-002520-13-Outside-EU/EEABaxalta Innovations GmbH
进行中（未招募）
4 期
A Post-marketing study receiving RIXUBIS as on-demand or Prophylaxis under standard clinical practice in patients with Hemophilia BCTRI/2018/07/014754Baxalta Innovations GmbH
进行中（未招募）
1 期
Study the effect of Landiolol on elevated heart rate by septic shock patientsAdult patients in ICU with septic shock who remain tachycardic (HR =95 bpm) and require vasopressor therapy to maintain a Mean arterial pressure (MAP) of =65 mmHg after a hemodynamic optimization period (at least 12 hours and up to 36 hours).MedDRA version: 20.0Level: PTClassification code 10043071Term: TachycardiaSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 23.1Level: PTClassification code 10040070Term: Septic shockSystem Organ Class: 10021881 - Infections and infestationsEUCTR2017-002138-22-PLAOP Orphan Pharmaceuticals AG200
进行中（未招募）
1 期
Study the effect of Landiolol on elevated heart rate by septic shock patientsAdult patients in ICU with septic shock who remain tachycardic (HR =95 bpm) and require vasopressor therapy to maintain a Mean arterial pressure (MAP) of =65 mmHg after a hemodynamic optimization period (at least 12 hours and up to 36 hours).MedDRA version: 20.0Level: PTClassification code 10043071Term: TachycardiaSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10040070Term: Septic shockSystem Organ Class: 10021881 - Infections and infestationsEUCTR2017-002138-22-EEAOP Orphan Pharmaceuticals AG200